Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Non Operating Income (2021 - 2025)

Historic Non Operating Income for Intellia Therapeutics (NTLA) over the last 5 years, with Q3 2025 value amounting to $10.2 million.

  • Intellia Therapeutics' Non Operating Income rose 1208.88% to $10.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.9 million, marking a year-over-year increase of 11344.01%. This contributed to the annual value of $15.2 million for FY2024, which is 5530.07% down from last year.
  • According to the latest figures from Q3 2025, Intellia Therapeutics' Non Operating Income is $10.2 million, which was up 1208.88% from $8.7 million recorded in Q2 2025.
  • Over the past 5 years, Intellia Therapeutics' Non Operating Income peaked at $10.2 million during Q3 2025, and registered a low of -$7.9 million during Q2 2024.
  • For the 5-year period, Intellia Therapeutics' Non Operating Income averaged around $3.1 million, with its median value being $6.5 million (2025).
  • Its Non Operating Income has fluctuated over the past 5 years, first crashed by 230601.72% in 2022, then surged by 46403.03% in 2023.
  • Quarter analysis of 5 years shows Intellia Therapeutics' Non Operating Income stood at -$822000.0 in 2021, then crashed by 303.89% to -$3.3 million in 2022, then surged by 332.86% to $7.7 million in 2023, then fell by 2.35% to $7.5 million in 2024, then skyrocketed by 34.49% to $10.2 million in 2025.
  • Its Non Operating Income stands at $10.2 million for Q3 2025, versus $8.7 million for Q2 2025 and $6.5 million for Q1 2025.